Gengwei Huo - Publications

Cost-effectiveness of first-line treatments for metastatic pancreatic cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 09, 2026

Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC.

Journal: Expert review of anticancer therapy

Published: January 09, 2026

Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.

Journal: Frontiers in pharmacology

Published: August 12, 2025

cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment.

Journal: Communications biology

Published: July 25, 2025

Efficacy and safety of antibody drug conjugate therapy in patients with human epidermal growth factor receptor 2-positive non-small cell lung cancer: A single-arm systematic review and meta-analysis.

Journal: Oncology letters

Published: April 12, 2025

Adagrasib in the treatment of KRASG12C-mutated non-small cell lung cancer: a cost-effectiveness analysis.

Journal: Translational cancer research

Published: April 08, 2025

Trastuzumab Deruxtecan and Sacituzumab Govitecan for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer: A Cost-Effectiveness Analysis.

Journal: Clinical therapeutics

Published: October 11, 2024

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer.

Journal: Frontiers in pharmacology

Published: February 26, 2024

Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis.

Journal: Translational lung cancer research

Published: January 03, 2024

Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.

Journal: Journal of gynecologic oncology

Published: January 02, 2024

Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.

Journal: Journal of gynecologic oncology

Published: December 07, 2023

Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

Journal: Journal of gynecologic oncology

Published: November 21, 2023